Pharmaceutical Company UCB Inc. Settles Health Care Fraud Allegations
AUGUSTA ? Attorney General William J. Schneider announced today that Maine reached an agreement with pharmaceutical manufacturer UCB Inc. (UCB) to settle allegations of submitting false claims for its epilepsy drug Keppra to MaineCare, the Maine Medicaid program.
Medicaid programs nationwide will receive approximately $25.7 million of the $34 million settlement resolving criminal and civil liability arising out of UCB?s off-label promotion of its anti-epileptic drug. Maine will receive approximately $43,000 as a result of the settlement.